We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results:1-10 of 504

USPTO director talks trademark clutter, Uber declares itself a verb, and beware sketchy Chinese licenses: news round-up
  • World Trademark Review
  • USA, Australia, Thailand, Uruguay, Bulgaria, China, Ecuador, European Union, Global
  • September 25 2018

Every Tuesday and Friday, World Trademark Review presents a round-up of news, developments and insights from across the trademark sphere. In our


FDA Statement Regarding Quality Assurance Efforts for Foreign Drug Manufacturing Facilities
  • Knobbe Martens
  • USA, European Union
  • September 19 2018

On September 5, 2018, the Food and Drug Administration (FDA) published a press release highlighting recent actions taken to ensure that


How the U.S. Compares to Europe on Biosimilar Approvals and Products In the Pipeline
  • Rothwell, Figg, Ernst & Manbeck, PC
  • USA, European Union
  • August 2 2018

As pharmaceutical drug costs attract increasing media attention and political scrutiny, a growing number of biosimilar drugs are set to enter the U.S


Pharmaceuticals and Brexit: Keeping the industry healthy
  • Linklaters LLP
  • United Kingdom, European Union
  • June 19 2018

It is estimated that each month 37 million packs of medicines are supplied from European countries to the UK with 45 million heading in the other


Life Sciences International Review Q2 2018
  • Morgan Lewis
  • USA, United Kingdom, European Union, France
  • June 6 2018

The most-significant recent development is the entry into force on 25 May of the EU General Data Protection Regulation. This new legislation will have


How the U.S. Compares to Europe on Biosimilar Approvals and Products In the Pipeline
  • Rothwell, Figg, Ernst & Manbeck, PC
  • USA, European Union
  • May 1 2018

As pharmaceutical drug costs attract increasing media attention and political scrutiny, a growing number of biosimilar drugs are set to enter the U.S


New EFSA Report Finds Antimicrobial Resistance Persists in Humans, Animals and Food
  • Keller and Heckman LLP
  • USA, European Union
  • March 1 2018

Antimicrobial use in food-producing animals remains a hot button issue. In the United States, FDA, USDA, and various industry stakeholders have sought


Something Rotten in Denmark? The International Criminalization of Drug Advertising
  • Morvillo Abramowitz Grand Iason & Anello PC
  • USA, European Union
  • February 20 2018

Sometimes, when it comes to drafting posts for The Insider, a little digging can turn up remarkable results. This week’s post demonstrates the point


International Life Sciences Review: Issue 8
  • Morgan Lewis
  • USA, Netherlands, China, European Union, France, Global
  • February 6 2018

The European Commission has published the Draft Regulation amending Regulation (EC) No 8472000 as regards the definition of the concept 'similar


Update: How the U.S. Compares to Europe on Biosimilar Approvals and Products In the Pipeline
  • Rothwell, Figg, Ernst & Manbeck, PC
  • USA, European Union
  • January 24 2018

As pharmaceutical drug costs attract increasing media attention and political scrutiny, a growing number of biosimilar drugs are set to enter the U.S